Clinical Trial

A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 21, 2025 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to evaluate the reasonable dosage, efficacy and safety of Linperlisib in combination with rituximab in subjects with relapsed/refractory (R/R) indolent non-hodgkin lymphoma(NHL) in adults.
Trial Details
NCT Number NCT06981988
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Relapsed/Refractory Indolent NHL
Enrollment 80 participants
Start Date 2025-06
Primary Completion 2025-08 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-05-21